Clinical trials: CNLC IIIA Stage
Resectable Hepatocellular Carcinoma, Macrovascular Invasion
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
At the time of diagnosis, the majority of hepatocellular carcinoma (HCC) patients are at the intermediate to advanced stages, with a 50-70% incidence of macrovascular invasion (including portal vein, hepatic vein, inferior vena…
- Conditions
- Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
- Trial name
- NCT06524466
- Testing
- Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University